Modified immune cells tested in leukemia that stopped responding to CD19 therapy
Tests modified T cells in people with CD19-negative acute lymphoblastic leukemia.
Plain-language title generated from the registry record
Registry title: CAR-T Immunotherapy Targeting CD19- ALL
Key facts
- Where
- Shenzhen, ChinaSee the site
- Phase
- Phase 1/2
Where in China
- Shenzhen Geno-immune Medical InstituteShenzhen, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shenzhen Geno-Immune Medical Institute
- Trial code
- NCT04016129
- Record updated
- 2 November 2026
- Original description
This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 negative ALL that express CD22, CD123, CD38, CD10, CD20 and TSLPR, as many patients developed CD19-negative disease after CD19 CART immunotherapy. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.Read full original descriptionShow less
CART Immunotherapy Targeting CD19 Negative Acute Lymphoblastic Leukemia
This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 negative ALL that express CD22, CD123, CD38, CD10, CD20 and TSLPR, as many patients developed CD19-negative disease after CD19 CART immunotherapy. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.
Inclusion: Age older than 6 months; Native CD19 negative B cell malignancies or relapse after CD19-CAR-T immunotherapy; Malignant B cells expressing one or more of the following surface molecules: CD22/CD123/CD38/CD10/CD20/TSLPR; The KPS score over 80 points, and survival time is more than 1 month; Greater than Hgb 80 g/L; No contraindications to blood cell collection.
Exclusion: Under systemic steroid use within a week of the treatment; Complications with other active diseases, and difficult to assess patient response; Bacteria, fungus, or virus infection, and unable to control; Living with HIV; Active HBV and HCV infection; Pregnant and nursing mothers.